ROCKWELL MEDICAL, INC. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Rockwell Medical reported Q2 2026 net sales of $17.8M (11% YoY growth) with gross margin expanding to 18% from 16% YoY, driven by lower manufacturing costs and higher volume. Net loss improved to $1.2M (Q2 2025: $1.5M). Cash position stood at $24.8M at June 30, 2026. The company reiterates 2026 guidance: $70–75M net sales, 18–22% gross margin, $1–2M Adjusted EBITDA, and positive operating cash flow. Two customer agreements were announced: three-year purchase agreement with Heritage Dialysis and a two-year renewal with aQua Dialysis. A 1-for-10 reverse stock split became effective July 1, 2026 to regain Nasdaq compliance; the company subsequently regained compliance with the $1.00 minimum bid price requirement.
Why this rating
Revenue growth and margin expansion are encouraging for a $28.7M market-cap company, but still loss-making; modest customer wins and cash generation are operational positives balanced against need for profitability and Nasdaq compliance crisis.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.